Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)
出版年份 2017 全文链接
标题
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)
作者
关键词
Gastric adenocarcinoma, S-1, Trastuzumab, Neuregulin1, First-line chemotherapy
出版物
Gastric Cancer
Volume 21, Issue 1, Pages 84-95
出版商
Springer Nature
发表日期
2017-05-11
DOI
10.1007/s10120-017-0725-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK)
- (2016) Mayuko Saito et al. ACTA ONCOLOGICA
- Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?
- (2016) Takeshi Yamada et al. JOURNAL OF GASTROENTEROLOGY
- Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
- (2015) M.-H. Ryu et al. ANNALS OF ONCOLOGY
- Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
- (2015) Jun Zhou et al. JOURNAL OF GASTROENTEROLOGY
- Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
- (2014) Zhi Peng et al. Biomarkers in Medicine
- Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
- (2014) Y Kurokawa et al. BRITISH JOURNAL OF CANCER
- Evaluation of serum HER2-ECD levels in patients with gastric cancer
- (2014) Katsunobu Oyama et al. JOURNAL OF GASTROENTEROLOGY
- Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells
- (2014) Myoung-Eun Han et al. JOURNAL OF GASTROENTEROLOGY
- Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
- (2012) Kensei Yamaguchi et al. Gastric Cancer
- Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
- (2011) Akira Sawaki et al. Gastric Cancer
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Study of inhibition effect of Herceptin on interaction between Heregulin and ErbB Receptors HER3/HER2 by single-molecule force spectroscopy
- (2009) Xiaoli Shi et al. EXPERIMENTAL CELL RESEARCH
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started